Lilly eases investors' jitters with strong 2017 forecast

Eli Lilly and Co, in a move that appeared to ease investor concerns after the failure of its high-profile Alzheimer's drug, on Thursday provided a 2017 forecast above Wall Street estimates and expressed confidence in recently launched products and those in development. Lilly shares jumped 5.7 percent to $71.51. "We are encouraged by Lilly's 2017 financial guidance," Leerink Partners analyst Seamus Fernandez said in a research note.